Hyperinsulinemia reduces hepatic SHBG and lowers total testosterone.

Hyperinsulinemia and insulin resistance directly impair the liver's ability to produce sex hormone-binding globulin (SHBG). This reduction in SHBG leads to a corresponding decrease in circulating total testosterone, creating a biochemical profile that can mimic androgen deficiency.

Mechanistic basis of SHBG suppression

The suppression of SHBG by insulin resistance is not a direct hormonal inhibition but rather a consequence of metabolic shifts in the liver.

• Transcriptional Silencing: In states of insulin resistance, high levels of glucose and fructose drive hepatic de novo lipogenesis (DNL). This process increases levels of palmitoyl-CoA, a lipid intermediate that reduces the expression of hepatocyte nuclear factor-4α (HNF-4α).
• Promoter Displacement: HNF-4α is a critical activator for the SHBG gene. When its levels drop, it is replaced at the SHBG promoter by the repressor COUP-TF1, effectively silencing the production of the protein.
• Biomarker Utility: Because of this specific pathway, low SHBG levels are considered a robust clinical biomarker for hepatic insulin resistance and metabolic dysfunction-associated steatotic liver disease (MASLD).

Impact on total testosterone levels

SHBG serves as the primary transport protein for testosterone, and its concentration dictates the total amount of hormone circulating in the blood.

• Metabolic Clearance: SHBG stabilizes testosterone and protects it from rapid degradation. When SHBG levels fall, the metabolic clearance rate (MCR) of testosterone increases, causing total testosterone levels to drop.
• Homeostatic Reset: A decline in SHBG initially increases the "free" or unbound fraction of testosterone. This triggers negative feedback to the hypothalamus and pituitary, which reduces gonadotropin stimulation of the testes. This continues until a new equilibrium is reached where free testosterone is normalized, but total testosterone remains significantly low.

Functional androgen deficiency considerations

The clinical significance of low total testosterone in the context of insulin resistance depends on the distinction between total and bioavailable hormone levels.

• "Pseudo-hypogonadism": Many men with insulin resistance exhibit low total testosterone but maintain normal levels of free (bioavailable) testosterone. This state, often called "eugonadal pseudo-hypogonadism," typically presents with an intact hypothalamic-pituitary-testicular axis and normal LH/FSH levels.
• Diagnostic Criteria: True functional androgen deficiency requires both low biochemical levels and consistent clinical symptoms (e.g., reduced libido, fatigue). If the reduction in SHBG is severe enough that the body cannot maintain adequate free testosterone levels, it then contributes to a true functional deficiency.

Bottom line

Hyperinsulinemia suppresses hepatic SHBG production via lipogenesis-driven transcriptional silencing. This lower SHBG level causes a decrease in total testosterone by increasing its clearance, though individuals may remain functionally "eugonadal" if their free testosterone levels are maintained within the normal range.